Patent ID: 6528623
Filing Date: 2003-03-04
Classification: A61K,A61P,C07K

Abstract:
A humanized monoclonal antibody comprising a humanized heavy chain and a humanized light chain:(1) the humanized light chain comprising three complementarity determining regions (CDR1, CDR2, and CDR3) having amino acid sequences from the corresponding complementarity determining regions of a light chain of a nonhuman antibody that specifically binds to an extracellular domain of an ACT-4-L-h-1 ligand, and having a variable region framework substantially identical to a human light chain variable region framework sequence; and (2) the humanized heavy chain comprising three complementarity determining regions (CDR1, CDR2, and CDR3) having amino acid sequences from the corresponding complementarity determining regions of a heavy chain of the nonhuman antibody, and having a variable region framework sequence substantially identical to a human heavy chain variable region framework sequence; wherein the humanized antibody specifically binds to the extracellular domain of the ACT-4-L-h-1 ligand with a binding affnity having a lower limit of 107 Mâˆ’1 and an upper limit that is within five-fold of the binding affinity of the nonhuman antibody.